Pathos AI collects $365M to fuel 'bulletproof' oncology trials and in-license more cancer drugs
作者：May 15, 2025 10:44 AM EDTUpdated 10:54 AM FinancingStartupsAI
Pathos AI, seeking to upend cancer drug development with artificial intelligence and large multimodal models, has raised the third-largest private funding round in biotech so …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
关于《Pathos AI collects $365M to fuel 'bulletproof' oncology trials and in-license more cancer drugs》的评论
暂无评论
发表评论
摘要
Pathos AI has raised the third-largest private funding round in biotech by leveraging artificial intelligence and large multimodal models to revolutionize cancer drug development.